6月16日 - ** 药物开发商KalVista Pharmaceuticals KALV.O盘前下跌约7.4%，至12美元 ** 美国食品和药物管理局（FDA）以工作量大、资源有限为由，延长了对KALV公司实验性药物sebetralstat的审查。 * (link) * 卫生部长小罗伯特-肯尼迪（Robert F. Kennedy Jr. ** TD Cowen 表示，推迟上市似乎与药物的安全性或疗效无关。 ** 券商表示："虽然令人失望，但我们预计对上市影响不大。 ** 该公司称，FDA 计划在四周内做出决定 ** KALV 今年累计上涨 53
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.